Dataset Information

Kwang2003 - The influence of RKIP on the ERK signaling pathway

ABSTRACT: Kwang2003 - The influence of RKIP on the ERK signaling pathway This model is described in the article: Mathematical Modeling of the Influence of RKIP on the ERK Signaling Pathway Kwang-Hyun Cho, Sung-Young Shin, Hyun-Woo Kim, Olaf Wolkenhauer, Brian McFerran and Walter Kolch Computational Methods in Systems Biology: First International Workshop, CMSB 2003 Rovereto, Italy, February 24â??26, 2003 Proceedings Abstract: This paper investigates the influence of the Raf Kinase Inhibitor Pro- tein (RKIP) on the Extracellular signal Regulated Kinase (ERK) signaling pathway through mathematical modeling and simulation. Using nonlinear ordi- nary differential equations to represent biochemical reactions in the pathway, we suggest a technique for parameter estimation, utilizing time series data of proteins involved in the signaling pathway. The mathematical model allows the simulation the sensitivity of the ERK pathway to variations of initial RKIP and ERK-PP (phosphorylated ERK) concentrations along with time. Throughout the simulation study, we can qualitatively validate the proposed mathematical model compared with experimental results. This model is hosted on BioModels Database and identified by: BIOMD0000000647. To cite BioModels Database, please use: Chelliah V et al. BioModels: ten-year anniversary. Nucl. Acids Res. 2015, 43(Database issue):D542-8. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

SUBMITTER: Emma Fairbanks

PROVIDER: BIOMD0000000647 | BioModels | 2019-03-21

REPOSITORIES: BioModels

ACCESS DATA

Similar Datasets

Project description:About 50% of human malignancies exhibit unregulated signalling through the Ras-ERK1/2 (ERK) pathway, as a consequence of activating mutations in members of Ras and Raf families. However, the quest for alternative Ras-ERK pathway-directed therapies is desirable. Upon phosphorylation ERK dimerize. We had previously demonstrated that dimerization is essential for ERK extranuclear but not nuclear signaling. Furthermore, by molecular biology approaches, we showed that specifically inhibiting ERK extranuclear component, by impeding ERK dimerization, is sufficient for curtailing tumor progression. Here, we have identified a small molecule inhibitor for ERK dimerization in vitro and in vivo that, without affecting ERK phosphorylation, prevents tumorigenesis driven by Ras-ERK pathway oncogenes, both in cellular and animal models. Importantly, this compound is unaffected by resistance-acquisition processes that hamper “classical” Ras-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two novel concepts in cancer therapy: 1) The blockade of sublocalization-specific sub-signals, rather than total signals, as a means of effectively counteracting oncogenic Ras-ERK signaling. 2) Targeting regulatory protein-protein interactions such as dimerization, rather than catalytic activities, within a signaling route, as an approach for producing effective anti-tumoral agents. Strategies aimed at preventing aberrant flux through this route remain an attractive option for therapeutic intervention in cancer. In this respect, drugs inhibiting the kinase activities of BRaf and MEK have yielded promising results. A375p cells treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours. mRNA from A375p cells was extrated using RNeasy mini kit (Qiagen, Germany) according to the manufacturer's instructions. Cells were previously treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours.

Dataset Information

Kwang2003 - The influence of RKIP on the ERK signaling pathway

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure